2023-01-25 19:55:10

Small Pharma, Inc's Psychedelics For Major Depression Trial Results And Q1 Earnings

Logo Benzinga
By Lara Goldstein

Short-acting psychedelics biotech Small Pharma Inc. DMTTFs proprietary intravenous (IV) DMT-based drug SPL026 delivered positive topline results in a Phase 2a trial for the treatment of Major Depressive Disorder (MDD).

The trial, which wasaimed to assess the efficacy and safety of IV SPL026, was paired with supportive therapy in 34 patients with moderate to severe MDD. Two-staged, the studyinvestigated the efficacy of a single dose with supportive therapy vs. placebo with therapy at two weeks post-dose.

Prior towithdrawing antidepressants from participants, the studys dose was a short IV infusion of 21.5mg of SPL026, translating to a 20 to 30-minute psychedelic experience.

The second, open-label phase had all participants enrolled and receive a single dose of SPL026 with supportive therapy, then followed up for a further 12 weeks. This stage allowed Small Pharma to assess the durability of the antidepressant effect as well as the comparative efficacy and safety of a one vs. two-dose regimen of its psychedelic compound.

Continue read on benzinga.com

Logo Daily Mail
HealthBy Caitlin Tilley2023-01-25 18:22:37
DMT the most potent psychedelic known to man treats people with severe depression after a single dose, a cutting-edge clinical trial suggests. Up to six in...

Logo Benzinga
Business / FinanceBy Lara Goldstein2023-01-25 17:02:57
Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First? Legislators in seven U.S. states are introducing...

Logo PR Newswire
HealthPress Release2023-01-24 13:07:00
The study will evaluate repeat low doses of psilocybin for safety, tolerability, and efficacy in treating generalized anxiety disorder (GAD) on a take-home...

Logo GlobeNewswire
SciencePress Release2023-01-25 13:30:00
Isranalytica 2023, the A nnual meeting of the Israel Analytical Chemical Society, provided Clearmind with the opportunity to garner visibility for its drug...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-25 10:55:00
WITHIN, a psychedelic medical clinic, retreat center and integration program based in Austin, Texas, has raised $1.1 million to expand its treatment...

Logo GlobeNewswire
SciencePress Release2023-01-25 09:00:00
HANNOVER, Germany, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Vakzine Projekt Management GmbH (VPM), a German drug development consultancy and service provider...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-24 18:12:00
The Phase 3 study conducted in the U.S. will assess the efficacy and safety of the first subcutaneous long-acting Injectable (LAI) formulation of olanzapine...

Logo PR Newswire
HealthPress Release2023-01-24 23:50:00
DUBLIN, Jan. 24, 2023 /PRNewswire/ -- The "Post-traumatic Stress Disorder Treatment Market, by Drug Class, by Route of Administration, by Age Group, by...

Logo PR Newswire
HealthPress Release2023-01-25 17:30:00
DUBLIN, Jan. 25, 2023 /PRNewswire/ -- The "Global Insomnia Market Size, Share & Industry Trends Analysis Report by Distribution Channel, Therapy Type,...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-25 13:04:00
Pioneering study to find new treatments for a devastating condition in Down syndrome Children's Hospital Los Angeles (CHLA) has launched the first clinical...

Logo PR Newswire
HealthPress Release2023-01-25 13:05:00
- Phase 2a '201' clinical trial will resume immediately at 50 and 100 mg doses- -Additional safety and pharmacokinetic information will be measured in...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-24 12:00:00
New Alberta regulations increase the need to educate doctors, psychiatrists, and nurse practitioners. CALGARY, AB, Jan. 24, 2023 /CNW/ - ATMA Journey Centers...

Logo Nasdaq
Business / FinanceBy Rtt News2023-01-25 13:14:19
(RTTNews) - Tango Therapeutics, Inc. (TNGX) Wednesday announced FDA clearance for its Investigational New Drug or IND application for TNG462, a...

Logo GlobeNewswire
EconomyPress Release2023-01-24 16:30:00
Depression Treatment Market Size By Product (TMS Devices and Drugs), By Indication (Major Depressive Disorder, Phobia, Obsessive-Compulsive Disorder, and...

Logo GlobeNewswire
SciencePress Release2023-01-25 13:03:00
Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy Bolsters Presence in Neuroscience...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-24 17:14:00
Submission of EXXUA (gepirone HCl), a novel targeted single serotonin receptor agonist for treatment of Major Depressive Disorder receives PDUFA action date...

Logo GlobeNewswire
SciencePress Release2023-01-25 12:00:00
TNG908 granted Orphan Drug Designation in U.S. for the treatment of malignant glioma BOSTON, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc....

Logo Benzinga
Business / FinanceBy Business Wire2023-01-25 11:50:00
Merck MRK, known as MSD outside of the United States and Canada, today announced that it will stop the Phase 3 KEYNOTE-991 trial investigating KEYTRUDA,...

Logo GlobeNewswire
SciencePress Release2023-01-25 13:00:00
Partner Sanofi has commenced dosing in a Phase 2 clinical trial of SAR443820 (DNL788) in individuals with multiple sclerosis Denali to receive a milestone...

Logo GlobeNewswire
SciencePress Release2023-01-25 13:37:00
Nes-Ziona, Israel, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the Company), a clinical-stage macrophage reprogramming...